November 28, 2014 2:38 AM ET

Life Sciences Tools and Services

Company Overview of SISCAPA Assay Technologies, Inc.

Company Overview

SISCAPA Assay Technologies, Inc. develops SISCAPA assays for high-value protein biomarkers and other proteins to enable precise measurement of human protein in clinical and other samples. The company offers SISCAPA assay reagents, including RabMAb, which are rabbit monoclonal anti-peptide antibodies; and isotope standard labeled peptides, unlabelled peptides, and magnetic beads for protein biomarkers. Its products are also used in commercial applications. The company provides SISCAPA licenses to its partners that use the technology for commercial research purposes, or to commercialize SISCAPA reagents, kits, or assay services. SISCAPA Assay Technologies, Inc. was incorporated in 2011 and is ...

1759 Willard Street, NW

Washington, DC 20009

United States

Founded in 2011

Phone:

301-728-1451

Key Executives for SISCAPA Assay Technologies, Inc.

Co-Founder and Chief Executive Officer
Co-Founder and Chief Scientific Officer
Age: 68
General Manager
Compensation as of Fiscal Year 2014.

SISCAPA Assay Technologies, Inc. Key Developments

Agilent Technologies Inc. and SISCAPA Assay Technologies, Inc. Signs the Agreement for Multiplexed Protein Quantization Solution

Agilent Technologies, Inc.and SISCAPA Assay Technologies, Inc., or SAT have signed a non-exclusive agreement to enable SAT to provide a solution for multiplexed protein quantization using an automated workflow for SISCAPA LC-mass spectrometry. This solution will combine SAT's reagents for targeted protein quantization with Agilent's Bravo Automated Liquid Handling Platform for sample preparation, along with liquid chromatography-mass spectrometers (LC/MS) for quantitative analysis. The agreement expands on an established strategic relationship between Agilent and SAT, furthering both companies' ability to enhance customer workflows. SAT will provide an integrated solution for targeted protein measurement. A protocol for addition-only trypsin digestion followed by anti-peptide immunocapture enrichment has been developed for the Bravo platform and is complemented by a purpose-designed, intuitive software interface. The process supports preparation of 400 multiplexed samples per working day, with sensitive and selective mass analysis carried out using Agilent's triple quadrupole mass spectrometry instruments. SISCAPA assays alleviate challenges of limited specificity and protein interferences seen with ligand binding assays and anti-protein immunocapture mass spectrometry. Subjecting the sample to up-front tryptic digestion and enriching for proteotypic peptides means SISCAPA assays measure the amount of a protein target in a highly multiplexed and high-throughput manner, free of such interferences.

Agilent Technologies Inc. and SISCAPA Assay Technologies, Inc. Signs Non-Exclusive Agreement to Enhance Customer Workflows

Agilent Technologies Inc. and SISCAPA Assay Technologies announced they have signed a non-exclusive agreement to enable SAT to provide an end-to-end solution for multiplexed protein quantitation using a highly automated workflow for SISCAPA LC-mass spectrometry. This solution will combine SAT's reagents for targeted protein quantitation with Agilent's Bravo Automated Liquid Handling Platform for sample preparation, along with liquid chromatography--mass spectrometers (LC/MS) for quantitative analysis. The agreement expands on an established strategic relationship between Agilent and SAT, furthering both companies' ability to enhance customer workflows. SAT will provide an integrated solution for targeted protein measurement. A protocol for addition-only trypsin digestion followed by anti-peptide immunocapture enrichment has been developed for the Bravo platform and is complemented by a purpose-designed, intuitive software interface. The process supports preparation of 400 multiplexed samples per working day, with sensitive and selective mass analysis carried out using Agilent's triple quadrupole mass spectrometry instruments. SISCAPA assays alleviate challenges of limited specificity and protein interferences seen with ligand binding assays and anti-protein immunocapture mass spectrometry. Subjecting the sample to up-front tryptic digestion and enriching for proteotypic peptides means SISCAPA assays measure the amount of a protein target in a highly multiplexed and high-throughput manner, free of such interferences. This greatly decreases the bottleneck of screening candidate protein biomarkers in clinical research. SAT will offer complete systems comprised of its SISCAPA assay reagents combined with the Bravo platform and software and a broad offering of Agilent liquid chromatography and LC/MS systems including, but not limited to, Agilent's popular Triple Quadrupole LC/MS systems and RapidFire high throughput LC/MS system.

Bruker Announces Second-Phase Collaboration Agreement with SISCAPA Assay Technologies for Further Development and Commercialization of SISCAPA-MALDI Assays

At the 12th HUPO World Congress, Bruker Corporation announced the start of a second-phase collaboration agreement with SISCAPA Assays Technologies, Inc. (SAT). The ongoing collaboration aims to exploit the high throughput, robustness and ease of use of MALDI-TOF instruments as an alternative to nano-LC-MS technology currently used in many SISCAPA assays. Having confirmed the utility and quantitative precision of the SISCAPA-MALDI workflow, the second-phase collaboration will focus on a number of further developments involving the measurement of clinically useful biomarkers. All SISCAPA-MALDI assays are currently for research use only, and not for use in diagnostic procedures. Bruker plans to establish fully automated SISCAPA-MALDI capabilities in its demonstration facilities, allowing interested customers to evaluate SISCAPA-MALDI instrumentation and workflows. The demo facility will also enable high-level applications and service support for such customers by Bruker personnel. Assay Development: Additional SISCAPA assays will be validated and parameters, such as the limit of quantitation and limit of detection (LOQ/LOD), will be determined. Bruker and SAT also plan to enable third-party collaborators to develop SISCAPA-MALDI assays for accurate quantification of their own protein targets, for use in RUO and clinical research environments. Such assays would be useful for a diverse range of customers, e.g. those wishing to pursue protein quantitation for process optimization or large-scale clinical validation of protein biomarkers. Bruker and SAT also jointly plan to investigate the development of new assays for the SISCAPA-MALDI workflow. Of particular interest are assays of relevance to clinical microbiology, as the previous work has shown that such assays could be run on the benchtop microflex LT, the same mass spectrometer employed in the Bruker MALDI Biotyper. Successful validation and clearance for clinical use of such assays would immediately make them available to the more than 900 (and growing) clinical microbiology laboratories worldwide that already have a MALDI Biotyper installed.

Similar Private Companies By Industry

Company Name Region
ALT Bioscience LLC United States
ICON Clinical Research, Inc. United States
Kinexis, Inc. United States
Kineta, Inc. United States
SDI Trialytics, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 11, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SISCAPA Assay Technologies, Inc., please visit www.siscapa.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.